STAYBLE THERAPEUTICS Aktie

 

Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma idag den 5 juni 2025 på Bolagets kontor i Göteborg. Vid stämman fattades beslut om huvudsakligen nedanstående. Fastställande av räkenskaperna Årsstämman fastställde resultat- och balansräkningen för Bolaget för 2024. Styrelsens ledamöter och verkställande direktören beviljades ansvarsfrihet för räkenskapsåret 2024.   Resultatdisposition Årsstämman beslutade, i enlighet med styrelsens förslag, att årets resultat ska balanseras i ny räkning.   Styrelse och revisorer Årsstämman beslutade, i...

Stayble Therapeutics AB ("Stayble" eller "Bolaget") offentliggör härmed kvartalsrapport för första kvartalet 2025. Rapporten finns tillgänglig som bifogat dokument samt på Bolagets hemsida, www.staybletherapeutics.com/sv/investerare/finansiella-rapporter/. Nedan följer en sammanfattning av rapporten. Sammanfattning   Väsentliga händelser under första kvartalet (januari - mars 2025) · I januari meddelades att ett vetenskapligt abstrakt gällande STA363s effekt på diskvolymsminskning från fas 1b accepterades för en muntlig presentation vid International Society for the Study of the...

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2024. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick. Staybles årsredovisning för 2024 finns nu tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och kan även distribueras i tryckt format till aktieägare som så önskar.   For more information Andreas Gerward, CEO of Stayble Therapeutics AB Mail: andreas.gerward@stayble.se Phone:...

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I STAYBLE THERAPEUTICS AB (PUBL). SE ÄVEN AVSNITTET ”VIKTIG INFORMATION”...

Aktieägarna i Stayble Therapeutics AB (publ), org.nr 559024-8372, kallas till årsstämma den 5 juni 2025 kl. 13.00 på bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg. Inregistrering till årsstämman påbörjas kl. 12.30. Rätt att delta och anmälan Den som önskar delta på bolagsstämman ska: · dels vara införd i den av Euroclear Sweden AB förda aktieboken den 27 maj 2025; · dels senast den 30 maj 2025 anmäla sin avsikt att delta i årsstämman till Stayble Therapeutics AB, ”Årsstämma”, Lennart Torstenssonsgatan 8, 412 56 Göteborg, eller via e-post andreas.gerward@stayble.se....

Stayble Therapeutics AB ("Stayble" eller "Bolaget") har beslutat att senarelägga publiceringen av bolagets årsredovisning för 2024 på grund av pågående emission. Bolaget angav tidigare att årsredovisningen skulle publicerats imorgon den 7 maj 2025. Ny publiceringsdag är den 14 maj 2025.     For more information Andreas Gerward, CEO of Stayble Therapeutics AB Mail: andreas.gerward@stayble.se Phone: +46 730 808 397   About Stayble Therapeutics AB Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for lumbar disc herniation (LDH)....

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I STAYBLE THERAPEUTICS AB (PUBL). SE ÄVEN AVSNITTET ”VIKTIG INFORMATION”...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2024. The report is available as an attached document and on the Company's website, https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report. Summary   Highlights during the fourth quarter (October – December 2024) · In October, the European Patent Office (EPO) announced an "Intention to Grant" for the Company's patent for treating disc herniation with STA363. "Intention to Grant" means that only a formal process remains before the Company...

EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA, RYSSLAND, BELARUS ELLER NÅGON ANNAN JURISDIKTION DÄR SÅDAN PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE SKULLE VARA I STRID MED GÄLLANDE REGLER ELLER KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER ÄN VAD SOM FÖLJER AV SVENSK RÄTT. DETTA PRESSMEDDELANDE UTGÖR INTE ETT ERBJUDANDE ATT FÖRVÄRVA VÄRDEPAPPER I STAYBLE THERAPEUTICS AB (PUBL). SE ÄVEN AVSNITTET ”VIKTIG INFORMATION”...

Stayble Therapeutics AB ("Stayble" or "the Company") announces that its scientific abstract on the effect of STA363 on disc volume reduction in patients with lumbar disc herniation has been accepted for an oral presentation at the Annual Meeting of the International Society for the Study of the Lumbar Spine (ISSLS) in Atlanta, USA, May 12–16, 2025. The abstract, titled “Intradiscal STA363 in patients with radiculopathy caused by lumbar disc herniation produces volume reduction consistent with symptomatic relief”, presents findings on disc volume reduction following intradiscal injection of...

Stayble Therapeutics AB ("Stayble" or "the Company") has interviewed Rachelle, a US Payer Expert about her view on the US market, challenges in the market and the potential of STA363. This interview is part of an interview series with previous interviews: · CEO Andreas Gerward was interviewed regarding the partnering process by Kalqyl, available at the following link (Swedish): https://www.youtube.com/watch?v=eCzjXXUJHOQ · Interview with Jane Buus Laursen – an experienced pharma dealmaker and Board member of Stayble, available at the following link (English): https://...

Stayble Therapeutics AB ("Stayble" or "the Company") has interviewed Jane Buus Laursen about her view from an experienced dealmaker's perspective on STA363 and our coming partnering process. This interview is part of an interview series with a previous interview of CEO Andreas Gerward performed by Kalqyl, available at the following link (Swedish): https://www.youtube.com/watch?v=eCzjXXUJHOQ   Introduction to Jane Buus Laursen Jane has been part of Stayble's Board since 2018, and she contributes with her extensive knowledge of business development and partnering processes in pharma...

Stayble Therapeutics AB ("Stayble" or "the Company") today announces the intensification of its partnering activities with the company's drug candidate STA363 in collaboration with a renowned transaction advisor. The company's objective for the STA363 pain project is to identify a partner with the appropriate expertise and financial resources to advance the clinical development of STA363 towards commercialization. According to the board and management, interest from potential stakeholders has significantly increased since Stayble presented the positive results from the company's Phase 1b...

Stayble Therapeutics AB ("Stayble" or "the Company") CEO, Andreas Gerward, presented (in Swedish) the Company, the results from phase 1b, and the path forward at Financial Stockholm's event "Invest Like the Pros" on December 11, 2024. Watch the recorded presentation below: https://www.youtube.com/watch?v=41H9eQ57mlc   For more information Andreas Gerward, CEO of Stayble Therapeutics AB Mail: andreas.gerward@stayble.se Phone: +46 730 808 397     About Stayble Therapeutics AB Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for...

Stayble Therapeutics AB ("Stayble" or the "Company") has previously announced positive results from the Company's clinical phase 1b study in lumbar disc herniation (LDH). The study met its primary safety and tolerability endpoint. Additional data exhibit several positive outcomes, including a promising statistically significant reduction in disc volume compared to placebo-treated patients, and further analysis has generated key learnings regarding MRI changes that give STA363 critical competitive advantages. CEO Andreas Gerward, comments The additional analysis strengthens our belief in...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the third quarter of 2024. The report is available as an attached document and on the Company's website: https://staybletherapeutics.com/investor-relations/financial-reports/. Below is a summary of the report. Summary   Highlights during the second quarter (July – Septmeber 2024) · July: Erik Kullgren was announced as the new CFO, effective August 1, 2024.  · September: The South African Patent Office became the first authority to approve the Company's patent for the treatment of pain...

Stayble Therapeutics AB ("Stayble" or the "Company") announces positive results from the Company's clinical phase 1b study in lumbar disc herniation (LDH). The study met its primary safety and tolerability endpoint. Additionally, STA363-treated patients showed a statistically significant reduction in disc volume compared to placebo-treated patients. The study met its primary endpoint with an established favorable safety profile. Only a few adverse events (AE) and no sustained serious adverse events (SAE) related to STA363 were recorded during the study. Data show a statistically...

Stayble Therapeutics AB (“Stayble” or “the Company”) announced today that the European Patent Office (EPO) has issued an "Intention to Grant" for the Company's patent for the treatment of disc herniation with STA363. "Intention to Grant" means that only a formal process remains before Stayble can receive approved patents in countries affiliated with the EPO. The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides IP protection until 2040. Additionally, there is the possibility of applying for a five-year patent...

Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the last patient visit has been completed in the phase 1b study involving patients with pain caused by herniated discs. This company follows the previously communicated timeline and expects to present results during the fourth quarter of 2024. A total of 25 patients were included, and 22 completed their 6-month follow-up, meaning the goal of having at least 18 evaluable patients in the study has been achieved.   CEO Andreas Gerward commented: "I am very proud that we have conducted our clinical study according...

Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the South African patent office, as the first country, has approved the Company's patent for the treatment of herniated discs with STA363. This approval is a significant milestone for the Company and follows a previous positive international search report from European authorities. With these advancements, we see strong potential to obtain several additional national patent approvals. The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides...